Literature DB >> 476222

Dopamine-beta-hydroxylase in the cerebrospinal fluid: relationship to disulfiram-induced psychosis.

L F Major, P Lerner, J C Ballenger, G L Brown, F K Goodwin, W Lovenberg.   

Abstract

Cerebrospinal fluid (CSF) dopamine-beta-hydroxylase (DBH) activity in 32 male alcoholics was measured using a modification of the radioenzymatic method of Molinoff et al. In most, the CSF was obtained before treatment with disulfiram, while in others it was obtained while they were on the drug (250 or 500 mg). As expected, treatment with this reversible DBH inhibitor had no effect on the activity of the enzyme measured in our in vitro assay. However, low pretreatment DBH activity was found to correlate with adverse reactions to disulfiram. Mean DBH activity of four individuals who went on to become psychotic on disulfiram was 0.13 +/- 0.02 nmole/ml per hr (mean +/- SEM). An additional four individuals who developed dysphoric but nonpsychotic reactions had a mean DBH of 0.23 +/- 0.03. Both these values were significantly lower than the mean DBH activity of the remaining 24 individuals treated with disulfiram who had no adverse side effects, 0.53 +/- 0.06 p less than 0.02 and p less than 0.05, respectively, 2-tailed t-test.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 476222

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  12 in total

Review 1.  Pharmacotherapeutics directed at deficiencies associated with cocaine dependence: focus on dopamine, norepinephrine and glutamate.

Authors:  Colin N Haile; James J Mahoney; Thomas F Newton; Richard De La Garza
Journal:  Pharmacol Ther       Date:  2012-01-31       Impact factor: 12.310

Review 2.  [Pharmacotherapy of schizophrenia and comorbid substance use disorder. A systematic review].

Authors:  T Wobrock; R D'Amelio; P Falkai
Journal:  Nervenarzt       Date:  2008-01       Impact factor: 1.214

3.  Disulfiram attenuates drug-primed reinstatement of cocaine seeking via inhibition of dopamine β-hydroxylase.

Authors:  Jason P Schroeder; Debra A Cooper; Jesse R Schank; Megan A Lyle; Meriem Gaval-Cruz; Yvonne E Ogbonmwan; Nikita Pozdeyev; Kimberly G Freeman; P Michael Iuvone; Gaylen L Edwards; Philip V Holmes; David Weinshenker
Journal:  Neuropsychopharmacology       Date:  2010-08-25       Impact factor: 7.853

4.  A phase I study to repurpose disulfiram in combination with temozolomide to treat newly diagnosed glioblastoma after chemoradiotherapy.

Authors:  Jiayi Huang; Jian L Campian; Amit D Gujar; David D Tran; A Craig Lockhart; Todd A DeWees; Christina I Tsien; Albert H Kim
Journal:  J Neurooncol       Date:  2016-03-10       Impact factor: 4.130

5.  Effects of dopamine beta-hydroxylase genotype and disulfiram inhibition on catecholamine homeostasis in mice.

Authors:  Brooke N Bourdélat-Parks; George M Anderson; Zoe R Donaldson; Jay M Weiss; Robert W Bonsall; Milburn S Emery; L Cameron Liles; David Weinshenker
Journal:  Psychopharmacology (Berl)       Date:  2005-10-22       Impact factor: 4.530

6.  Linkage analysis of plasma dopamine β-hydroxylase activity in families of patients with schizophrenia.

Authors:  Joseph F Cubells; Xiangqing Sun; Wenbiao Li; Robert W Bonsall; John A McGrath; Dimitri Avramopoulos; Virginia K Lasseter; Paula S Wolyniec; Yi-Lang Tang; Kristina Mercer; Ann E Pulver; Robert C Elston
Journal:  Hum Genet       Date:  2011-04-21       Impact factor: 4.132

7.  Neuronal copper homeostasis susceptibility by genetic defects in dysbindin, a schizophrenia susceptibility factor.

Authors:  Avanti Gokhale; Alysia Vrailas-Mortimer; Jennifer Larimore; Heather S Comstra; Stephanie A Zlatic; Erica Werner; Daniel F Manvich; P Michael Iuvone; David Weinshenker; Victor Faundez
Journal:  Hum Mol Genet       Date:  2015-07-21       Impact factor: 6.150

8.  Clinical features of methamphetamine-induced paranoia and preliminary genetic association with DBH-1021C→T in a Thai treatment cohort.

Authors:  Rasmon Kalayasiri; Viroj Verachai; Joel Gelernter; Apiwat Mutirangura; Robert T Malison
Journal:  Addiction       Date:  2014-03-17       Impact factor: 6.526

Review 9.  Human genetics of plasma dopamine beta-hydroxylase activity: applications to research in psychiatry and neurology.

Authors:  J F Cubells; C P Zabetian
Journal:  Psychopharmacology (Berl)       Date:  2004-04-16       Impact factor: 4.530

10.  Pharmacoprophylaxis of alcohol dependence: Review and update Part I: Pharmacology.

Authors:  Sandeep Grover; Gaurav Bhateja; Debasish Basu
Journal:  Indian J Psychiatry       Date:  2007-01       Impact factor: 1.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.